Tissue Diagnostics Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Product (Consumables (Antibodies, Kits, Probes, Reagents), Instruments (Slide Scanners, Slide Staining Systems, Tissue Microarrays, Tissue, Processing Systems), Other), By Technology (Digital Pathology And Workflow Management, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Primary Special Staining), By Application (Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Others), By End-User (Contract Research Organizations (CROs), Hospitals, Pharmaceutical Organization, Research Laboratories), And By Geography - Forecasts From 2023 To 2028

  • Published : Aug 2023
  • Report Code : KSI061610034
  • Pages : 140

The tissue diagnostics market was valued at US$1.468 billion in 2021 and is expected to grow at a CAGR of 7.81% over the forecast period to reach a market size of US$2.484 billion by 2028.

The tissue diagnostics market refers to the industry that involves the development, production, and commercialization of diagnostic tests and tools used to examine tissue samples to diagnose diseases or assess various medical conditions. This market includes multiple products such as instruments, consumables, accessories, and technologies like immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining techniques. Tissue diagnostics play a crucial role in areas such as cancer diagnosis, infectious disease diagnosis, autoimmune disease diagnosis, cardiovascular disease diagnosis, and more. 

Increasing prevalence and incidence of chronic diseases.

The rising prevalence of chronic diseases, including cancer, cardiovascular diseases, and neurological disorders, has propelled the demand for tissue diagnostics to unprecedented heights. Globally, chronic diseases are responsible for 74% of all deaths annually, resulting in the loss of approximately 41 million lives, as the World Health Organization (WHO) reported. Tissue diagnostics, comprising a range of histopathological techniques and molecular assays, are pivotal in facilitating accurate disease diagnosis and tailored treatment strategies. The intricate nature of these chronic conditions necessitates a comprehensive understanding of the underlying tissue abnormalities and molecular alterations, which can be effectively achieved through tissue diagnostics.

The growing geriatric population.

Additionally, the growing population of individuals aged 60 years and older has increased in 2021. As this age group is more susceptible to developing cancer, the rising population size underscores the increased demand for tissue diagnostics services. Healthcare providers and diagnostic companies must adapt and expand their resources to meet the growing need for accurate cancer diagnosis and treatment decision-making. Advancements in tissue diagnostic technologies can play a crucial role in addressing the burden of cancer in these demographics and improving patient outcomes.

Favorable government initiatives:

Governments worldwide are increasingly recognizing the potential of tissue diagnostics technologies, including their significant impact on healthcare and disease management. These technologies offer valuable insights into disease diagnosis, personalized treatment planning, and monitoring patient response to therapy. Governments aim to enhance healthcare outcomes and improve patient care by supporting the adoption and advancement of tissue diagnostics.

Key players in the tissue diagnostics market  

Key players in the tissue diagnostics market include Abbott Laboratories, Agilent Technologies, BD (Becton, Dickinson, and Company), BioGenex, and Cardinal Health. These companies invest heavily in research and development to develop new technologies and solutions to meet the growing demand. For instance, in 2021, "Ventana HER2 Dual ISH DNA Probe Cocktail" was launched by Roche Diagnostics, a subsidiary of F. Hoffmann-La Roche Ltd. This product is used to detect human epidermal growth factor receptor 2 (HER2) gene amplification in breast and gastric cancer tissue samples. It provides clinicians with valuable information for determining the appropriate treatment approach, such as targeted therapies like HER2 inhibitors. 

Significant increase in diagnostic innovation

The previous few years have seen a significant increase in diagnostic innovation, due to which major corporations have introduced advanced products for the growing immunohistochemistry (IHC) market. For instance, the DISCOVERY ULTRA system by Roche enhances the capacity to execute manual and completely automated experiments concurrently without experiencing synchronization issues because of its 30 independent slide drawers. A wide variety of IHC and ISH experiments, comprising FISH, protein IHC/ISH, and multiplex assays, among others, can be fully automated using the system. Similarly, Creative Diagnostics released a comprehensive array of immunohistochemistry pathology antibodies in December 2021.

Hospitals use tissue diagnostic solutions at high rates.

Tissue-based diagnostic testing by hospitals is replacing more conventional testing techniques. This is because tissue diagnostic tests take less time than traditional techniques. the rising prevalence of chronic diseases also increases the demand for tissue diagnostics in hospitals. For instance, an estimated 1.9 million new cancer cases were identified in 2022, according to Cancer Facts and Figures 2022, released in January 2022 by the American Cancer Society. The rising incidence of cancer and the heavy load of other chronic diseases enhance the need for precise diagnosis and treatment.

Geographical Insights:

Based on geography, the tissue diagnostics market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The North American region, particularly the United States, has a well-established healthcare infrastructure and advanced diagnostic technologies, making it a prominent market for tissue diagnostics. Europe is another significant market for tissue diagnostics, with countries like Germany, France, and the United Kingdom leading in terms of market size and advancements in diagnostic technologies. The region benefits from a strong focus on early disease diagnosis, well-established healthcare systems, and increasing cancer screening and prevention awareness.

The United States is at the forefront of the tissue diagnostics market, representing North America's largest and most dynamic market. With its advanced healthcare infrastructure, extensive research and development capabilities, and high prevalence of cancer, the country offers a fertile ground for the growth and innovation of tissue diagnostics. The United States houses numerous leading players in the industry, driving competition and technological advancements. The emphasis on precision medicine and personalized healthcare further propels the adoption of tissue diagnostics as healthcare providers strive for accurate diagnoses and tailored treatment approaches. With a strong focus on research, collaborations, and cutting-edge technologies, the United States plays a pivotal role in shaping the future of tissue diagnostics, improving patient outcomes, and advancing the field of healthcare diagnostics. 

Market Developments:

  • In May 2021, QIAGEN, a global leader in molecular diagnostics, made a significant contribution to the market by launching their therascreen® KRAS RGQ PCR Kit as the first US FDA-approved tissue companion diagnostic for NSCLC tumors. This innovative solution identifies the KRAS G12C mutation, a prevalent mutation in NSCLC, and provides crucial insights for guiding treatment decisions.
  • One of the advanced diagnostics for personalized medicine, Oncotype DX, for instance, analyses 21 genes to identify breast cancer patients who can be treated without chemotherapy. In 2021, personalized medicines received almost a third of all FDA approvals for new drugs and over 25% of all FDA approvals over the previous seven years. Major pharmaceutical firms like AstraZeneca confirm precision therapies provide about 90% of their research and development income. 

Tissue Diagnostics Market Scope:


Report Metric Details
Market Size Value in 2021 US$1.468 billion
Market Size Value in 2028 US$2.484 billion
Growth Rate CAGR of 7.81% from 2021 to 2028
Base Year 2021
Forecast Period 2023 – 2028
Forecast Unit (Value) USD Billion
Segments Covered Product, Technology, Application, End-Users, and Geography
Regions Covered North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered Abbott Laboratories, Agilent Technologies, Inc., BD (Becton, Dickinson, and Company), BioGenex, Cardinal Health, Danaher, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Medtronic, Merck KGaA, Thermo Fisher Scientific Inc.
Customization Scope Free report customization with purchase


Market Segmentation:

  • By Product
    • Consumables
      • Antibodies
      • Kits
      • Probes
      • Reagents
    • Instruments
      • Slide Scanners
      • Slide Staining Systems
      • Tissue Microarrays
      • Tissue Processing Systems
    • Others
  • By Technology
    • Digital Pathology and Workflow Management
    • Immunohistochemistry (IHC)
    • In Situ Hybridization (ISH)
    • Primary Special Staining
  • By Application
    • Breast cancer
    • Cervical cancer
    • Colorectal cancer
    • Gastric cancer
    • Lung cancer
    • Others
  • By End-Users
    • Contract Research Organizations (CROs)
    • Hospitals
    • Diagnostic Centers
    • Others
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Others
    • Middle East and Africa
      • UAE
      • Saudi Arabia
      • Others
    • Asia Pacific
      • Japan
      • China
      • South Korea
      • India
      • Others

Frequently Asked Questions (FAQs)

The tissue diagnostics market is expected to reach a total market size of US$2.484 billion in 2028.
The global tissue diagnostics market is expected to grow at a CAGR of 7.81% over the forecast period.
Tissue Diagnostics Market was valued at US$1.468 billion in 2021.
The global tissue diagnostics market has been segmented by product, technology, application, end-users, and geography.
With an increased incidence of cancer, the market for tissue diagnostics markets has witnessed promising growth and is further estimated to grow during the forecast period.


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Design

2.2. Research Data

2.3. Validation


3.1. Key Findings


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Consumables

5.2.1. Antibodies

5.2.2. Kits

5.2.3. Probes

5.2.4. Reagents

5.3. Instruments

5.3.1. Slide Scanners

5.3.2. Slide Staining Systems

5.3.3. Tissue Microarrays

5.3.4. Tissue Processing Systems

5.3.5. Others


6.1. Introduction

6.2. Digital Pathology and Workflow Management

6.3. Immunohistochemistry (IHC)

6.4. In Situ Hybridization (ISH)

6.5. Primary Special Staining


7.1. Introduction

7.2. Breast cancer

7.3. Cervical cancer

7.4. Colorectal cancer

7.5. Gastric cancer

7.6. Lung Cancer

7.7. Others


8.1. Introduction

8.2. Contract Research Organizations (CROs)

8.3. Hospitals

8.4. Diagnostic Centers

8.5. Others 


9.1. Introduction

9.2. North America

9.2.1. By Product

9.2.2. By Technology

9.2.3. By Application

9.2.4. By End-User

9.2.5. By Country United States Canada Mexico

9.3. South America

9.3.1. By Product

9.3.2. By Technology

9.3.3. By Application

9.3.4. By End-User

9.3.5. By Country Brazil Argentina Others

9.4. Europe

9.4.1. By Product

9.4.2. By Technology

9.4.3. By Application

9.4.4. By End-User

9.4.5. By Country Germany France United Kingdom Italy Others

9.5. Middle East and Africa

9.5.1. By Product

9.5.2. By Technology

9.5.3. By Application

9.5.4. By End-User

9.5.5. By Country UAE Saudi Arabia Others

9.6. Asia Pacific

9.6.1. By Product

9.6.2. By Technology

9.6.3. By Application

9.6.4. By End-User

9.6.5. By Country Japan China South Korea India Others


10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix


11.1. Abbott Laboratories

11.2. Agilent Technologies, Inc.

11.3. BD (Becton, Dickinson, and Company)

11.4. BioGenex

11.5. Cardinal Health

11.6. Danaher

11.7. Exact Sciences Corporation

11.8. F. Hoffmann-La Roche Ltd

11.9. Medtronic

11.10. Merck KGaA

11.11. Thermo Fisher Scientific Inc.

Abbott Laboratories

Agilent Technologies, Inc.

BD (Becton, Dickinson, and Company)


Cardinal Health


Exact Sciences Corporation

F. Hoffmann-La Roche Ltd


Merck KGaA

Thermo Fisher Scientific Inc.